Skip to Content

NovoLog FlexPen Side Effects

Generic Name: insulin aspart

Note: This page contains side effects data for the generic drug insulin aspart. It is possible that some of the dosage forms included below may not apply to the brand name NovoLog FlexPen.

It is possible that some side effects of NovoLog FlexPen may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

For the Consumer

Applies to insulin aspart: subcutaneous solution

As well as its needed effects, insulin aspart (the active ingredient contained in NovoLog FlexPen) may cause unwanted side effects that require medical attention.

If any of the following side effects occur while taking insulin aspart, check with your doctor immediately:

More common
  • Anxious feeling
  • behavior change similar to being drunk
  • blurred vision
  • cold sweats
  • confusion
  • convulsions (seizures)
  • depression
  • difficulty with thinking
  • dizziness or lightheadedness
  • drowsiness
  • excessive hunger
  • fast heartbeat
  • headache
  • irritability or abnormal behavior
  • nightmares
  • restless sleep
  • shakiness
  • slurred speech
  • tingling in the hands, feet, lips, or tongue
  • unconsciousness
Less common or rare
  • Depression of the skin at the place of injection
  • dryness of the mouth
  • fast or weak pulse
  • feeling of pressure, itching, redness, soreness, stinging, swelling, or tingling at the place of injection
  • increased thirst
  • irregular heartbeat
  • loss of appetite
  • mood or mental changes
  • muscle cramps or pain
  • nausea or vomiting
  • shortness of breath
  • skin rash or itching over the whole body
  • sweating
  • thickening of the skin at the place of injection
  • unusual tiredness or weakness
  • wheezing

For Healthcare Professionals

Applies to insulin aspart: subcutaneous solution

General

Adverse reactions observed have included hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus.[Ref]

Hypersensitivity

Hypersensitivity side effects have included both local and systemic reactions. Anaphylaxis has been reported. Local reactions have presented as erythema, local edema, and pruritus at the injection site. Most minor reactions to insulin at the injection site resolve in a few days to a few weeks.

Generalized allergy to insulin may present as a whole body rash, dyspnea, wheezing, hypotension, tachycardia, or diaphoresis. In clinical trials, allergic reactions were reported in 0.7% (10/1394) patients receiving insulin aspart (the active ingredient contained in NovoLog FlexPen) [Ref]

Very rare (less than 0.01%): Anaphylaxis
Frequency not reported: Allergic reactions[Ref]

Metabolic

Weight gain has been reported with insulin therapy and has been attributed to the anabolic effects of insulin and the decrease in glucosuria.[Ref]

Very common (10% or more): Hypoglycemia
Frequency not reported: Weight gain[Ref]

Cardiovascular

Common (1% to 10%): Chest pain
Uncommon (0.1% to 1%): Peripheral edema[Ref]

Insulin may cause sodium retention and edema, especially as metabolic control is improving.[Ref]

Dermatologic

Long-term use of insulin may cause lipodystrophy at the site of repeated injection. Lipodystrophy includes lipohypertrophy, a thickening of adipose tissue, and lipoatrophy, thinning of adipose tissue.[Ref]

Common (1% to 10%): Skin disorder
Uncommon (0.1% to 1%): Urticaria, rash
Frequency not reported: Lipodystrophy including lipohypertrophy and lipoatrophy[Ref]

Immunologic

Common (1% to 10%): Onychomycosis
Frequency not reported: Anti-insulin antibody titers[Ref]

The clinical significance of the development of these antibody titers is unknown.[Ref]

Ocular

Rapid improvement in glucose control has been associated with a transitory, reversible ophthalmologic refraction disorder and worsening of diabetic retinopathy. However, long-term glycemic control decreases the risk of diabetic retinopathy.[Ref]

Uncommon (0.1% to 1%): Refraction disorder, worsening of diabetic retinopathy[Ref]

Nervous system

Rapid improvement in glucose control has been associated with a transitory, reversible acute painful peripheral neuropathy. However, long-term glycemic control decreases the risk.[Ref]

Very common (10% or more): Headache (up to 12%)
Common (1% to 10%): Hyporeflexia, sensory disturbance
Rare (less than 0.1%): Painful peripheral neuropathy[Ref]

Gastrointestinal

Common (1% to 10%): Nausea, diarrhea, abdominal pain[Ref]

Genitourinary

Common (1% to 10%): Urinary tract infection[Ref]

References

1. "Product Information. Novolog (insulin aspart)" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.

2. Cerner Multum, Inc. "Australian Product Information." O 0

3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web1)